CAZ-AVI + Metronidazole + Meropenem

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
76
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Complicated Intra-Abdominal Infection

Conditions

Complicated Intra-Abdominal Infection

Trial Timeline

Mar 1, 2012 โ†’ Apr 1, 2014

About CAZ-AVI + Metronidazole + Meropenem

CAZ-AVI + Metronidazole + Meropenem is a phase 3 stage product being developed by Pfizer for Complicated Intra-Abdominal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01499290. Target conditions include Complicated Intra-Abdominal Infection.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01499290Phase 3Completed